Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Moderna stock is shedding 10% after a blistering cancer vaccine run, and the question now is whether profit takers know something the bulls don't ahead of a critical trial readout later this month.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo